Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors

Journal of Patient-Reported Outcomes

Table 2 Correlations among QLQ-CIPN20, PRO-CTCAE numbness and tingling items, TNSc©, and worst CIPN pain intensity scores

Measure	PRO-CTCAE numbness and tingling items		0–10 worst CIPN pain intensity	QLQ-CIPN20		TNSc©
Measure	Severity	Interference	0–10 worst CIPN pain intensity	Sensory	Motor	TNSc©
PRO-CTCAE Severity	1	0.59	0.65	0.72	0.50	0.48
PRO-CTCAE Interference		1	0.55	0.53	0.58	0.30
0–10 Worst CIPN Pain Intensity			1	0.56	0.40	0.27
QLQ-CIPN20 Sensory				1	0.56	0.48
QLQ-CIPN20 Motor					1	0.40
TNSc©						1

Table describes correlations among the PRO-CTCAE Numbness and Tingling Severity and Interference Items, QLQ-CIPN20, 0–10 worst CIPN pain intensity NRS (n = 138), and TNSc© (n = 118) at T3
CIPN-Chemotherapy-Induced Peripheral Neuropathy, PRO-CTCAE™—Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events, QLQ-CIPN20-Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Scale, TNSc©—Total Neuropathy Score-Clinical Version